Lyndra’s Series E Cash Expected To Get Weekly Risperidone To An FDA Filing

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.

Money in sack on wooden table
Lyndra raises $101m in private equity cash while awaiting Phase III data

Through years of private equity fund raises and partnerships, Lyndra Therapeutics has been building up its strategy to bring once-weekly or monthly oral medications to the health care system. With a $101m series E fundraising and a related commercial rights alliance with Sun Pharmaceutical Industries Ltd. unveiled on 21 December, the Watertown, MA-based company appears to be getting closer to that goal.

Key Takeaways

  • Drug delivery specialist Lyndra raises $101m in series E cash, with some of the money coming from Sun Pharma in exchange for commercial rights to its lead product candidate.

In January, Lyndra plans to release data from a Phase III pharmacokinetic study of LYN-005, its weekly, oral formulation of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.